RxDoctor Payments Data

Axel Ruiz-Tellez, MD

Family Medicine · Lehigh Acres, FLNPI 1184671034

Payments from drug & device makers

$4,228in general payments, 2019–2025

Across 89 payments — averaging $47.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$837
  • Amgen$816
  • Johnson & Johnson$433
  • AbbVie$311
  • Novo Nordisk$297
  • GSK$270
  • plus $1K from 12 others

What the payments were for

  • Food & beverage$4,228100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,228 in reported general payments places this provider in the 85th percentile of 7,282 family medicine providers in Florida.

See all family medicine providers in Florida

Medicare billing

Part B allowed, 2024
$93,688
Medicare patients
173
Services billed
1,154

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EnbrelEtanercept13$106,896
XolairOmalizumab13$105,676
OtezlaApremilast15$72,912
JardianceEmpagliflozin26$41,808
JanuviaSitagliptin Phosphate24$39,374
EliquisApixaban34$38,943
MounjaroTirzepatide17$24,125
FarxigaDapagliflozin Propanediol23$21,639
TrulicityDulaglutide20$18,401
XareltoRivaroxaban19$15,634
OzempicSemaglutide11$14,365
Bydureon BciseExenatide Microspheres15$12,458
Dexlansoprazole DrDexlansoprazole21$9,584
VascepaIcosapent Ethyl12$9,230
Lantus SolostarInsulin Glargine,hum.Rec.Anlog17$3,331

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AmgenEnbrel, Otezla$816$179,80828 claims
Lilly USA, LLCMounjaro, Trulicity$177$42,52637 claims
Boehringer IngelheimJardiance$158$41,80826 claims
PfizerEliquis$150$38,94334 claims
AstraZenecaFarxiga$837$21,63923 claims
Johnson & JohnsonXarelto$433$15,63419 claims
Novo NordiskOzempic$297$14,36511 claims
AbbVieSynthroid$311$1,10312 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 7,282 family medicine providers in Florida.

Other family medicine in Lehigh Acres

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →